首页> 外文期刊>Biomaterials >Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy
【24h】

Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy

机译:载桑朴龙脑两性淀粉胶束和阿霉素透明质酸纳米颗粒组装的桑树样双药复杂纳米载体,用于肿瘤联合治疗和靶向治疗

获取原文
获取原文并翻译 | 示例
           

摘要

A comprehensive strategy for the preparation of mulberry-like dual-drug complicated nanocarriers (MLDC NCs) with high drug loading and adjustable dual-drug ratio was developed. First, apogossypolone (ApoG2) amphiphilic starch micelles (AASt MCs) were prepared by self-assembly process, and doxorubicin (DOX) hyaluronic acid nanoparticles (DHA NPs) were prepared by DOX absorption with excess HA by electrostatic absorption. MLDC NCs were obtained by adsorption of 8-9 DHA NPs around one AASt MC via electrostatic interaction. UV-visible and fluorescence spectrophotometers were used to measure the entrapment efficiency and loading efficiency of the two drugs. Transmission electron microscope and dynamic light scattering method were used to observe the size distribution and morphology of the particles. The tumor-targeting feature caused by HA-receptor mediation was confirmed by in vitro cell uptake and in vivo near-infrared fluorescence imaging. MLDC NCs were found to possess a mulberry-like shape with a dynamic size of 83.1 +/- 6.6 nm. The final encapsulation efficiencies of ApoG2 and DOX in MLDC NCs were 94 +/- 1.7% and 87 +/- 5.8% with respect to drug-loading capacities of 13.3 +/- 1.2% and 13.1 +/- 3.7%, respectively. Almost no ApoG2 release was found within 80 h and less than 30% of DOX was released into the outer phase even after 72 h. In vivo fluorescence imaging revealed that MLDC NCs had highly efficient targeting and accumulation at the tumor in vivo and was maintained for 96 h after being injected intravenously in mice. Low LD50 for the two drugs in MLDC NCs was found after acute toxicity test. One-fifth normal dosage of the two drugs in MLDC NCs exhibited significantly higher anti-tumor efficiency in reducing tumor size compared with free drugs combination or single drug-loaded nanoparticles individually, indicating that the mulberry-like dual-drug nanoplatform has a great potential in tumor therapy. (C) 2014 Elsevier Ltd. All rights reserved.
机译:提出了制备载药量高,可调节双药比的桑树样双药复合纳米载体(MLDC NCs)的综合策略。首先,通过自组装方法制备了载脂磷灰酮(ApoG2)两亲性淀粉胶束(AASt MCs),并通过DOX吸收和静电吸附过量的HA制备了阿霉素(DOX)透明质酸纳米颗粒(DHA NPs)。 MLDC NCs是通过静电相互作用在一个AASt MC周围吸附8-9个DHA NP而获得的。使用紫外可见分光光度计和荧光分光光度计测量两种药物的包封效率和负载效率。用透射电子显微镜和动态光散射法观察颗粒的尺寸分布和形貌。 HA受体介导的肿瘤靶向特征已通过体外细胞摄取和体内近红外荧光成像得到证实。发现MLDC NC具有桑树状的形状,其动态尺寸为83.1 +/- 6.6 nm。相对于载药量分别为13.3 +/- 1.2%和13.1 +/- 3.7%,ApoG2和DOX在MLDC NC中的最终包封效率分别为94 +/- 1.7%和87 +/- 5.8%。在80小时内几乎未发现ApoG2释放,即使72小时后也只有不到30%的DOX释放到外相中。体内荧光成像显示,MLDC NCs在体内具有高效的靶向和在肿瘤处蓄积的能力,并且在小鼠静脉内注射后可维持96 h。急性毒性试验后,发现这两种药物在MLDC NCs中的LD50低。 MLDC NCs中两种药物的五分之一正常剂量与自由药物组合或单独载有药物的纳米颗粒相比,在减小肿瘤大小方面显示出显着更高的抗肿瘤效率,表明桑树样双药物纳米平台具有巨大潜力在肿瘤治疗中。 (C)2014 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号